Real-World Data Support Transplant Benefit in Unresectable CRLM : Liver Transpl | Feb 2026

Introduction

Colorectal Liver Metastases have historically been considered a contraindication to Liver Transplantation because of high recurrence risk and limited organ availability. However, modern systemic therapies, refined biologic selection and highly favorable outcomes from the TransMet trial have reignited interest in transplantation for carefully selected unresectable CRLM patients. The TransMet study reported unprecedented five-year survival exceeding 70%, challenging conventional transplant oncology paradigms.

Problem Statement

Although TransMet demonstrated promising survival outcomes, questions remain regarding external validity, reproducibility in real-world populations and the actual magnitude of transplant benefit compared with continued systemic chemotherapy. Robust prognostic stratification tools for patient selection also remain underdeveloped.

Summary

This multicenter international study provides the first external validation assessment of the TransMet selection criteria using a real-world cohort of 61 patients with unresectable CRLM undergoing liver transplantation across seven centers. Investigators used matching-adjusted indirect comparison methods to improve comparability between the real-world transplant cohort and the original TransMet population.

The results demonstrated remarkable consistency with the original TransMet findings. Five-year restricted mean survival time in the weighted real-world cohort closely mirrored outcomes observed in the TransMet liver transplantation arm, supporting reproducibility of the survival benefit outside specialized trial settings. Sensitivity analyses accounting for residual imbalance yielded similarly favorable long-term survival estimates.

Importantly, the study quantified transplant benefit relative to chemotherapy alone. Liver transplantation was associated with an estimated five-year survival gain exceeding 22 months compared with systemic therapy, reinforcing the substantial clinical impact of transplantation in highly selected patients with unresectable CRLM.

The analysis additionally identified several biologic factors associated with inferior post-transplant survival. KRAS Mutation emerged as one of the strongest adverse prognostic markers, consistent with prior colorectal oncology literature linking KRAS alterations to aggressive tumor biology and treatment resistance. Right-sided primary tumors also demonstrated poorer outcomes, further supporting the increasingly recognized prognostic divergence between right- and left-sided colorectal cancers.

Elevated carcinoembryonic antigen levels additionally appeared to predict worse post-transplant outcomes, suggesting that tumor biology rather than technical unresectability alone should drive transplant candidate selection. These findings strengthen the evolving concept of transplant oncology as a biologically guided discipline integrating molecular and clinical risk profiling.

The study is particularly important because it moves beyond simple survival reporting toward formal estimation of transplant benefit — a critical consideration given ongoing ethical concerns regarding organ allocation. Demonstrating substantial survival extension relative to systemic therapy strengthens the rationale for considering unresectable CRLM within future liver allocation frameworks, especially as outcomes now approach or exceed those achieved in several accepted transplant indications.

Nevertheless, the authors appropriately emphasize the need for larger multicenter datasets and more refined prognostic models. Recurrence after transplantation remains common in CRLM, and optimal integration of molecular biomarkers, chemotherapy response and disease kinetics into candidate selection algorithms is still evolving.

Overall, this first real-world validation study supports the external reproducibility of the TransMet trial findings and demonstrates meaningful transplant benefit in selected patients with unresectable colorectal liver metastases. The data further reinforce the emerging role of biologically driven transplant oncology and support continued evaluation of CRLM within future liver transplantation allocation and selection strategies.